Protillion Biosciences, a privately held biotech company working to identify and optimize new protein therapeutics and accelerate biologic research and development productivity, announced the completion of an $18 million Series A financing from ARCH Venture Partners and Illumina Ventures.

The Company's platform enables its commercial drug discovery partners to perform true quantitative analysis on complete protein libraries, producing actionable insights in days; a process that can take months using current industry best practices. Protillion's proprietary technology can generate and analyze massive experimental datasets at perfect amino acid resolution, enabling novel machine-learning approaches to antibody and binder discovery.